Lixisenatide Shows Promise in Phase 2 Trial as Adjunct Therapy for Early Parkinson Disease

Lixisenatide, commonly used to treat type 2 diabetes, has the ability to cross the blood brain barrier and has shown neuroprotective properties in preclinical models of PD.
August 28, 2023